Source comparison
Thymosin Alpha-1 Immune Modulation: Dosing Comparison
Chronic Hepatitis B (adjunct) 1.6 mg subcutaneous Twice weekly 24–52 weeks 15–20% increase in HBeAg seroconversion; 0.8–1.2 log₁₀ reduction in viral DNA Post-Chemotherapy Recovery 12–16 weeks 20–30% faster CD4+ reconstitution; reduced infection incidence Sever
This comparison does not assign a generated winner or score.
- Chronic Hepatitis B (adjunct)
- 1.6 mg subcutaneous
- Twice weekly
- 24–52 weeks
- 15–20% increase in HBeAg seroconversion; 0.8–1.2 log₁₀ reduction in viral DNA
- Post-Chemotherapy Recovery
- 12–16 weeks
- 20–30% faster CD4+ reconstitution; reduced infection incidence
- Severe Sepsis / Immune Paralysis
- 1.6 mg intravenous
- Daily
- 5–7 days
- Restoration of monocyte HLA-DR expression; 8–10% reduction in 28-day mortality
- HIV (experimental adjunct)
- Ongoing (maintenance)
- Partial restoration of CD4+/CD8+ ratio in treatment-experienced patients
- The 1.6 mg dose is the most extensively studied and represents the threshold for detectable immune modulation in clinical trials. Lower doses (0.8 mg or 0.9 mg) appear in older literature but show inconsistent results. Higher doses (3.2 mg) have been tested in sepsis protocols without additional benefit. The TLR9 and cytokine pathways appear to saturate at the 1.6 mg level.